Johnson & Johnson
PulseAugur coverage of Johnson & Johnson — every cluster mentioning Johnson & Johnson across labs, papers, and developer communities, ranked by signal.
1 day(s) with sentiment data
-
Zhongjiao Real Estate shifts to light-asset model; Johnson & Johnson invests in Acuvue
Zhongjiao Real Estate has announced a strategic shift to a light-asset operational model, focusing on property services, asset management, and operations. To reflect this change, the company's securities name will be up…
-
Johnson & Johnson invests $1B+ in ACUVUE contact lens production
Johnson & Johnson announced a significant investment of over $1 billion to expand its vision care product manufacturing facilities in Jacksonville, Florida. This expansion aims to increase the production capacity of ACU…
-
Demis Hassabis' Isomorphic Labs raises $2.1B for AI drug discovery
Isomorphic Labs, an AI drug discovery startup founded by Demis Hassabis, has secured $2.1 billion in Series B funding led by Thrive Capital. The company plans to use the new capital to scale its compute resources, gener…
-
Johnson & Johnson seeks AI marketing lead, boosting healthcare operations
Johnson & Johnson is actively seeking an Associate Director for AI marketing enablement, signaling a significant push to integrate AI into its core healthcare operations. This move highlights a broader trend among globa…
-
J&J CEO: US leads biopharma innovation, boosted by AI
Johnson & Johnson's CEO highlights America's leading role in biopharmaceutical innovation, with U.S. companies driving 55% of global R&D and launching most new medicines. Artificial intelligence is accelerating drug dis…
-
Johnson & Johnson completes clinical study for OTTAVA robotic surgical system
Johnson & Johnson has concluded a clinical study for its OTTAVA robotic surgical system. The study focused on the application of AI and robotics within medical science. Further details on the system's performance and im…
-
Johnson & Johnson uses AI to halve drug development analysis time
Johnson & Johnson is leveraging artificial intelligence to significantly speed up its drug development process. The company has reported a dramatic reduction in analysis time, cutting it from 700 hours down to approxima…
-
Palantir surges to $409B valuation, outpacing revenue growth
Palantir Technologies has achieved a significant market valuation, becoming one of the world's 25 most valuable companies despite its relatively small revenue compared to peers. The defense software firm reported its fi…